Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Herzog Highlights Approval of Olaparib/Bevacizumab as Frontline Maintenance in HRD+ Ovarian Cancer

May 9th 2020

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

Antibody-Drug Conjugate STRO-002 Active in Advanced Ovarian Cancer

May 9th 2020

The anti–folate receptor alpha antibody-drug conjugate STRO-002 showed early clinical promise in patients with advanced ovarian cancer.

Vaccine BVAC-C Shows Early Promise in Cervical Cancer

May 8th 2020

The vaccine BVAC-C demonstrated durable antitumor activity in patients recurrent cervical cancer.

Future Looks Bright in Endometrial Cancer, With Exciting Emerging Agents and Targets

May 6th 2020

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Salani Sheds Light on the Rising Role of Biomarkers in Cervical Cancer

May 5th 2020

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

IMRT Improves Patient-Reported Outcomes in Cervical and Endometrial Cancer

May 4th 2020

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.

Dr. Coleman on Recent Advancements Made in Cervical Cancer Treatment

May 2nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer

May 2nd 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

FDA Approves Niraparib for Frontline Maintenance in Ovarian Cancer

April 29th 2020

The FDA has approved niraparib for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy.

Trastuzumab Combo Paves Way for Novel Regimens in HER2+ Uterine Serous Carcinoma

April 28th 2020

Amanda Nickles Fader, MD, discusses the rationale for a phase II study and explains how the findings could open the door to other treatment options for women with uterine serous carcinoma.

Dostarlimab Active in dMMR Endometrial Cancer

April 25th 2020

The PD-1 inhibitor dostarlimab demonstrated clinically meaningful activity in patients with mismatch repair–deficient endometrial cancer.

Dr. Pothuri on the Importance of Obtaining Patient-Reported Outcomes in Ovarian Cancer

April 24th 2020

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Dr. Fader on Trastuzumab/Chemo in HER2+ Uterine Serous Carcinoma

April 24th 2020

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio

April 23rd 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

April 23rd 2020

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

FDA Approves New Use for cobas HPV Cervical Cancer Screening Test

April 21st 2020

The cobas HPV test for cervical cancer screening is now FDA-approved for use on the high-throughput cobas 6800/8800 Systems.

Niraparib Granted Priority Review in China for Frontline Maintenance in Ovarian Cancer

April 16th 2020

The China National Medical Products Administration has granted a priority review to niraparib for use as a frontline maintenance treatment for adult patients with advanced ovarian cancer.

Dr. Fader on the Rationale for Targeting HER2/neu in Uterine Serous Carcinoma

April 15th 2020

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Margarett C. Ellison, MD of Gynecologic Oncology of Tallahassee Joins Florida Cancer Specialists and Research Institute

April 15th 2020

Florida Cancer Specialists & Research Institute is pleased to announce the addition of gynecologic-oncologist Dr. Margarett C. Ellison in Tallahassee.

Dr. Chase on Toxicities With Niraparib in Ovarian Cancer

April 11th 2020

Dana Chase, MD, FACOG, discusses the safety profile of niraparib as frontline maintenance therapy in ovarian cancer.